Search

Your search keyword '"Ferrán Farrés M"' showing total 13 results
Start Over Author "Ferrán Farrés M"
13 results on '"Ferrán Farrés M"'

1. [Artículo traducido] Eficacia y seguridad del risankizumab en pacientes con psoriasis en el mundo real: un estudio retrospectivo, multicéntrico y no intervencionista

Author

Martorell-Calatayud, A., Santos-Alarcón, S., Sahuquillo-Torralba, A., Rivera-Díaz, R., Belinchón-Romero, I., Ruiz-Genao, D., Romero-Maté, A., Ruiz-Villaverde, R., Ferran-Farrés, M., Gallardo-Hernández, F., Almenara-Blasco, M., Suarez-Perez, J.A., González-Cantero, Á., Martínez-Lorenzo, E., Fernández-Armenteros, J.M., del Alcázar-Viladomiu, E., García-Latasa, J., Rocamora-Durant, V., Ara-Martín, M., Mateu-Puchades, A., Llamas-Velasco, M., Vilarrasa, E., Velasco-Pastor, M., De la Cueva, P., Carrascosa, J.M., and Magdaleno-Tapial, J.

Published
2025
Full Text
View/download PDF

2. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

Author

Martorell-Calatayud, A., Santos-Alarcón, S., Sahuquillo-Torralba, A., Rivera-Díaz, R., Belinchón-Romero, I., Ruiz-Genao, D., Romero-Maté, A., Ruiz-Villaverde, R., Ferran-Farrés, M., Gallardo-Hernández, F., Almenara-Blasco, M., Suarez-Perez, J.A., González-Cantero, Á., Martínez-Lorenzo, E., Fernández-Armenteros, J.M., del Alcázar-Viladomiu, E., García-Latasa, J., Rocamora-Durant, V., Ara-Martín, M., Mateu-Puchades, A., Llamas-Velasco, M., Vilarrasa, E., Velasco-Pastor, M., De la Cueva, P., Carrascosa, J.M., and Magdaleno-Tapial, J.

Published
2025
Full Text
View/download PDF

3. [Translated article] Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study

Author

Carretero Hernández, G., Ara Martín, M., Armesto Alonso, S., Belinchón Romero, I., Eiris Salvado, N., Ferrán Farrés, M., Galache Osuna, C., García Bustínduy, M., García Latasa de Araníbar, J., Juliá Manresa, M., Llamas Velasco, M., López Ferrer, A., Roncero Riesco, M., Ruiz Genao, D., Ruíz-Villaverde, R., Salgado Boquete, L., Soria Martínez, C., Vilarrasa Rull, E., and Descalzo, M.A.

Published
2025
Full Text
View/download PDF

4. Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional

Author

Carretero Hernández, G., Ara Martín, M., Armesto Alonso, S., Belinchón Romero, I., Eiris Salvado, N., Ferrán Farrés, M., Galache Osuna, C., García Bustínduy, M., García Latasa de Araníbar, J., Juliá Manresa, M., Llamas Velasco, M., López Ferrer, A., Roncero Riesco, M., Ruiz Genao, D., Ruíz-Villaverde, R., Salgado Boquete, L., Soria Martínez, C., Vilarrasa Rull, E., and Descalzo, M.A.

Published
2025
Full Text
View/download PDF

5. Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional

Author

Carretero Hernández, G, primary, Ara Martín, M, additional, Armesto Alonso, S, additional, Belinchón Romero, I, additional, Eiris Salvado, N, additional, Ferrán Farrés, M, additional, Galache Osuna, C, additional, García Bustínduy, M, additional, de Araníbar, J García Latasa, additional, Juliá Manresa, M, additional, Llamas Velasco, M, additional, López Ferrer, A, additional, Roncero Riesco, M, additional, Ruiz Genao, D, additional, Ruíz-Villaverde, R, additional, Salgado Boquete, L, additional, Soria Martínez, C, additional, Vilarrasa, E, additional, and Descalzo, MA, additional

Published
2024
Full Text
View/download PDF

6. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

Author

Ruiz-Genao, D.P., Carretero, G., Rivera, R., Ferrándiz, C., Daudén, E., de la Cuev, P., Belinchón, I., Gómez-García, F.J., Herrera-Acosta, E., López-Estebaranz, J.L., Ferrán-Farrés, M., Alsina, M., Baniandrés-Rodríguez, O., Sánchez-Carazo, J.L., Sahuquillo-Torralba, A., Rodriguez, L., Vilar-Alejo, J., García-Donoso, C., Carrascosa, J.M., Llamas-Velasco, M., Herrera-Ceballos, E., Botella-Estrada, R., Descalzo, M.A., and García-Doval, I.

Published
2020
Full Text
View/download PDF

7. Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm

Author

Ruiz-Genao, D.P., Carretero, G., Rivera, R., Ferrándiz, C., Daudén, E., de la Cueva, P., Belinchón, I., Gómez-García, F.J., Herrera-Acosta, E., López-Estebaranz, J.L., Ferrán-Farrés, M., Alsina, M., Baniandrés-Rodríguez, O., Sánchez-Carazo, J.L., Sahuquillo-Torralba, A., Rodriguez, L., Vilar-Alejo, J., García-Donoso, C., Carrascosa, J.M., Llamas-Velasco, M., Herrera-Ceballos, E., Botella-Estrada, R., Descalzo, M.A., and García-Doval, I.

Published
2020
Full Text
View/download PDF

8. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016

Author

Carretero Hernández, G., Ferrándiz, C., Rivera Díaz, R., Daudén Tello, E., de la Cueva-Dobao, P., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón Romero, I., López-Estebaranz, J.L., Alsina Gibert, M., Sánchez-Carazo, J.L., Ferrán Farrés, M., González Quesada, A., Carrascosa Carrillo, J.M., Llamas-Velasco, M., Mendiola Fernández, M.V., Ruiz Genao, D., Muñoz Santos, C., García-Doval, I., and Descalzo, M.A.

Published
2018
Full Text
View/download PDF

9. Descripción de los pacientes que reciben biológicos como primer tratamiento sistémico en el registro BIOBADADERM durante el periodo 2008-2016

Author

Carretero Hernández, G., Ferrándiz, C., Rivera Díaz, R., Daudén Tello, E., de la Cueva-Dobao, P., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón Romero, I., López-Estebaranz, J.L., Alsina Gibert, M., Sánchez-Carazo, J.L., Ferrán Farrés, M., González Quesada, A., Carrascosa Carrillo, J.M., Llamas-Velasco, M., Mendiola Fernández, M.V., Ruiz Genao, D., Muñoz Santos, C., García-Doval, I., and Descalzo, M.A.

Published
2018
Full Text
View/download PDF

10. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Betwswn 2008 and 2016

Author

Carretero Hernández G, Ferrándiz C, Rivera Díaz R, Daudén Tello E, de la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Belinchon I, López-Estebaranz JL, Alsina Gibert M, Sánchez-Carazo JL, Ferrán Farrés M, González Quesada A, Carrascosa Carrillo JM, Llamas-Velasco M, Mendiola Fernández MV, Ruiz Genao D, Muñoz Santos C, García-Doval I, Descalzo MA, and grupo de estudio de Biobadaderm

Subjects
Psoriasis, Psoriasis treatment, Bioiogy therapy, Biologks for psoriasis
Abstract

Introduction and objectives: Biologic drugs are usually prescribed as second-line treatment for psoriasis, that is, after the patient has first been treated with a conventional psoriasis drug. There are, however, cases where, depending on the characteristics of the patient or the judgement of the physician, biologics may be chosen as first-line therapy. No studies to date have analyzed the demographics or clinical characteristics of patients in this setting or the safety profile of the agents used. The main aim of this study was to characterize these aspects of first-line biologic therapy and compare them to those observed for patients receiving biologics as second-line therapy. Material and method: We conducted an observational study of 181 patients treated in various centers with a systemic biologic drug as first-line treatment for moderate to severe psoriasis between January 2008 and November 2016. All the patients were registered in the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology. Results: The characteristics of the first- and second-line groups were very similar, although the patients receiving a biologic as first-line treatment for their psoriasis were older. No differences were observed for disease severity (assessed using the PASI) or time to diagnosis. Hypertension, diabetes, and liver disease were all more common in the first-line group. There were no differences between the groups in terms of reasons for drug withdrawal or occurrence of adverse effects. Conclusions: No major differences were found between patients with psoriasis receiving biologic drugs as first- or second-line therapy, a finding that provides further evidence of the safety of biologic therapy in patients with psoriasis. Published by Elsevier Espana, S.L.U. on behalf of AEDV.

Published
2018

11. Real-world safety and efficacy of risankizumab in psoriatic patients: a multicenter, retrospective, and not-interventional study

Author

Martorell, A., Santos-Alarcón, S., Sahuquillo-Torralba, A., Rivera-Díaz, R., Belinchón-Romero, I., Ruiz-Genao, D., Romero-Maté, A., Ruiz-Villaverde, R., Ferrán-Farrés, M., Gallardo-Hernández, F., Almenara-Blasco, M., Alonso-Suárez, J., González-Cantero, Á., Martínez-Lorenzo, E., Fernández-Armenteros, J.M., de Alcázar-Viladomiu, E, García-Latasa, J., Rocamora-Durant, V., Ara-Martín, M., Mateu-Puchades, A., Llamas-Velasco, M., Vilarrasa-Rull, E., Velasco-Pastor, M., De la Cueva, P., Carrascosa, J.M., and Magdaleno-Tapial, J.

Abstract

Antecedentes: Risankizumab es un anticuerpo monoclonal humanizado que se dirige a la subunidad p19 de IL-23, recientemente aprobado para el tratamiento de la psoriasis en placas moderada a grave. Actualmente falta datos del mundo real basados en una muestra representativa de pacientes.

Published
2024
Full Text
View/download PDF

12. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Author

Baniandrés-Rodríguez O, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Nieto-Benito LM, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferrán Farrés M, Alsina M, Fernández-Freire LR, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Ruiz-Genao DP, Riera-Monroig J, Descalzo Gallego MÁ, and García-Doval I

Subjects
Adult, Aged, COVID-19 complications, Cohort Studies, Female, Humans, Incidence, Male, Middle Aged, Psoriasis complications, Registries, Severity of Illness Index, Spain, COVID-19 epidemiology, Psoriasis drug therapy
Published
2021
Full Text
View/download PDF

13. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.

Author

Daudén E, Carretero G, Rivera R, Ferrándiz C, Llamas-Velasco M, de la Cueva P, Belinchón I, Gómez-García FJ, Herrera-Acosta E, Ruiz-Genao DP, Ferrán-Farrés M, Alsina M, Baniandrés-Rodríguez O, Sánchez-Carazo JL, Sahuquillo-Torralba A, Fernández-Freire LR, Vilar-Alejo J, García-Donoso C, Carrascosa JM, Herrera-Ceballos E, López-Estebaranz JL, Botella-Estrada R, Segovia-Muñoz E, Descalzo MA, and García-Doval I

Subjects
Adult, Aged, Biological Therapy adverse effects, Cohort Studies, Female, Humans, Male, Middle Aged, Registries, Spain, Time Factors, Psoriasis drug therapy
Abstract

Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed., Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry., Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort., Results: Our study included 2845 patients (8954 treatment cycles; 9642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ classes, with a statistically significant decreased rate ratio (IRR of <1), whereas cyclosporine and infliximab had the highest, with an increased rate ratio (IRR of ≥5)., Limitations: Observational study, drug allocation not randomized, depletion of susceptibles, and prescribed doses not registered., Conclusion: Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products., (Copyright © 2020 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results